Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Multiple Cancer Types

The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).
Kidney (Renal Cell), Phase I
I
Beckermann, Kathryn
NCT04169711
VICCPHI2022

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: